Safety and Efficacy of DCB-BO1301 in Advanced Melanoma
Status:
Not yet recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
The primary study objectives are
1. to evaluate the safety and tolerability profiles of DCB-BO1301 and to determine the
maximum tolerated dose (MTD) of DCB-BO1301 as add-on therapy to dacarbazine in subjects
with advanced melanoma (Phase I)
2. to evaluate the efficacy profile of DCB-BO1301 at MTD or lower dose level as add-on
therapy to dacarbazine in subjects with advanced melanoma in terms of progression free
survival (Phase IIa)
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
A2 Healthcare Taiwan Corporation Chung Mei Biopharma Co., Ltd